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Abstract
Introduction: Thalassaemic osteopathy is a multifactorial disorder and limited
information exists about bone accrual and bone mineral density (BMD) in
prepubertal thalassaemic children. The study aimed to investigate some potential
genetic and biochemical bone markers as possible early predictors of BMD
variations in children with β-thalassaemia major (TM) before puberty. 
Material and methods: Thirt-one prepubertal children with β-TM, and 43 matched
controls were subjected to BMD assessment by dual energy X-ray absorptiometry
(DEXA). Vitamin D receptor (VDR) gene polymorphisms (Bsm1, Fok1) and the
biochemical bone markers serum osteocalcin and propeptide I procollagen (CPIP)
and urinary deoxypyridinoline (DPD) excretion were assessed.
Results: Bone mineral density was reduced in 25% of thalassaemics at the spine
and 15.4% at the hip region. Significantly higher levels of urinary DPD and lower
serum osteocalcin and CPIP levels were found in the studied thalassaemic
children compared to controls (p < 0.001). A significant negative correlation was
present between BMD in spine and hip and the patients’ age (r = –0.6367, 
p = 0.0002 and r = –0.616, p = 0.00079, respectively). There was a significant
reduction in BMD in males compared to females. Reduced BMD was more
frequent in male patients with genotypes bb and Ff but not in females. Bone
mineral density was not related to the studied biochemical bone markers, mean
pre-transfusion haemoglobin or serum ferritin. 
Conclusions: Routine BMD screening with DEXA is proposed to be a sensitive
predictor for early bone changes, particularly at the lumbar spine. DR gene
polymorphisms of Bsm1 and Fok1 polymorphisms may be determinants of BMD
in Egyptian prepubertal male thalassemics 
Key words: β-thalassaemia, bone mineral density, gene polymorphism vitamin D
receptor.
Introduction
Thalassaemia is a hereditary disease that causes chronic anaemia and
increased erythropoietin. Consequently, an expansion of bone marrow
spaces may contribute to osteopenia/osteoporosis [1]. Thalassaemic
osteopathy is a multifactorial disorder. The underlying disease, its
complications and management can contribute to its pathogenesis 
[2, 3]. The skeletal changes associated with untreated patients include
osteoporosis, growth failure, bone age delay and spondylometaphyseal
abnormalities [4]. Some published studies have confirmed deferoxamine-
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induced bone dysplasia [5]. Hypothalamic-pituitary-
gonadal axis and growth hormone dysfunction may
be responsible for the development of osteoporosis
in thalassaemic children and adolescents [6].
Regular transfusion and subcutaneous
deferoxamine chelation therapy have improved the
clinical picture and quality of life of thalassaemic
patients. However, osteopenia with cortical
thinning, increased trabeculation of the spine and
osteoporosis remain serious complications even in
well transfused and iron-chelated patients [7, 8].
Despite calcium and vitamin D administration,
effective iron chelation and normalization of
haemoglobin levels, patients with thalassaemia
major continue to lose bone mass [9]. Moreover,
twin studies have shown that osteoporosis is
a polygenic disorder. It is determined by the effects
of several genes, which account for 80% of the
variance in bone mineral density [10, 11]. Some loci,
such as the vitamin D receptor (VDR) gene as well
as collagen type I α I, are promising genetic
determinants of bone mass [12]. Vitamin D receptor
gene polymorphisms’ association with osteoporosis
is highly controversial. In humans, the VDR gene
has been located on the chromosome locus 12q13-
14. The gene is composed of a minimum of nine
exons. Vitamin D receptor gene start codon
polymorphisms and 3 end region polymorphism
may modulate bone density [13]. Clinical studies
have identified a range of regulatory and structural
VDR gene loci which are proposed to be involved in
bone density determination as length
polymorphism of COLI αI, Bsm1 and FokI [14]. The
VDR gene codes for the VDR protein which
regulates intestinal calcium absorption. However,
studies of the relationship between VDR gene
polymorphisms and bone density have been found
to be inconsistent and poorly reproducible 
in different populations, suggesting genetic
heterogeneity of osteoporosis [15]. Fok1 and Bsm1
polymorphisms are closely related to low bone
mineral density (BMD) and can be used as useful
genetic markers in determining risk of low BMD
and osteoporosis [16]. Bsm1 VDR gene
polymorphism is associated with osteopenia in
adult thalassaemic patients [2]. Fok1 VDR gene
polymorphism seems to directly affect bone mineral
accretion during pubertal growth through an effect
on calcium absorption. The relationship between
different genetic poly  morphisms and bone mineral
metabolism may vary with life stage [17]. Ferrari et
al. [18] reported that BMD is significantly associated
with VDR gene polymorphism only before puberty.
Limited information exists about bone accrual and
low bone mass in prepubertal β-thalassaemic
children. Therefore, this study was designed to
evaluate the skeletal changes in prepubertal
Egyptian children with β-thalassaemia major and
the possible role of Bsm1 and Fok1 polymorphisms
in the gene encoding the vitamin D receptor, and
the biochemical indices of bone metabolism were
studied as early predictors of BMD variation in this
young population.  
Material and methods
The present study is a case control study and was
carried out during the period from March 2005 to June
2007. The study was conducted on 31 chil  dren with
β-thalassaemia major (14 females and 17 males) at
the prepubertal age (mean age 9.74 ±2.85 years), on
transfusion therapy and chelated with subcutaneous
deferoxamine. They were recruited from regularly
treated patients in the Paediatric Haematology Unit,
Children’s Hospital, Ain Shams University and
Paediatric Haematology Clinic of the National
Research Centre in Egypt. Forty-three age- and sex-
matched children were included as controls. 
The included thalassaemic children and controls
were subjected to detailed history and clinical
examination. Data files of patients were revised 
for determination of mean pre-transfusion
haemoglobin and mean serum ferritin level in the
last year prior to the study.
•  Assessment of BMD using dual energy X-ray
(DEXA) absorptiometry technique (Norland XR-46,
version: 3.9.6/2.3.1.) was done on three sites
(lumbar spine, hip and femoral neck) in a medical
services unit in the National Research Centre; 
a Z-score 2.5 to –1 SD is referred to as normal
BMD,  Z-score < –1 to –2.5 SD is diagnoses
osteopenia and Z-score < –2.5 means osteoporosis
(WHO 2003).
• Blood and urine samples were assayed at the
Clinical Pathology Department in the National
Research Centre (Egypt). 
Assessment of bone turnover markers
Five millilitres of blood was withdrawn under
aseptic conditions by venipuncture from every child,
3 ml on EDTA for DNA extraction, 2 ml of blood was
centrifuged and sera were obtained and stored at
–20°C for assay of:
• osteocalcin as a marker of osteoblastic activity
and bone formation was measured using the host
ELISA kit (Biosource Europe S.A.), a quantitative
sandwich enzyme-linked immunosorbent assay;
• carboxy-terminal propeptide of type I procollagen
(CPIP) as a marker of bone formation. It was
measured using the METRA CICP EIA Kit (QUIDEL
Corp.)
All children were asked to void urine in special
tubes and urine samples were stored at –20°C.
Deoxypyridinoline cross links (DPD) level was
measured using the METRA DPD EIA Kit (QUIDEL
Corp.), as a marker of osteoclastic activity and bone
resorption. 
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Study of gene polymorphism of vitamin D
receptors Bsm1 and Fok1
DNA was extracted by using a spin column kit
(supplied from Qiagen): polymerase chain reaction
(PCR) amplification and enzymatic digestion of the
products with Bsm1 and Fok1.
For the Bsm1 polymorphism 2 mg of genomic
DNA was amplified with each of forward primer
5”AAGACTACAAGTACCGCGTCAGTG and reverse
primer 5”AACCAGCGGGAAGAGGTCAAGGG (supplied
by Biosynthesis). Polymerase chain reaction was
performed with a Bio  metra thermoblock, under
standard conditions, for 35 cycles, and with 65°C as
the annealing temperature. After amplification, the
PCR product (0.825 kb) was digested with restriction
endonuclease BsmI and electrophoresed in a 1.2%
agarose gel. With the enzyme Bsm1 (Fermentas,
Lithuania), the respective genotypes were defined
as B (indicating the absence of the restriction site)
or b (indicating the presence of the restriction site).
The PCR product for the Bsm1 polymorphism was
825 bp, and the restriction fragments were 650 bp
and 175 bp.
For the Fok1 polymorphism 2 mg of genomic DNA
was amplified with each of forward primer
5”AGCTGGCCCTGGCACTGACTCTGGCTCT and re  verse
primer 5”ATGGAAACACCTTGCTTCTTCTCCCTC. Pro  -
ducts were digested with restriction enzyme BseGI
(Fermentas, Lithuania), an isoschizomer of the FokI
enzyme, at 55°C for 120 min. Fragments were
electrophoresed through a 2% agarose gel containing
ethidium bromide, visualized, and photographed. The
presence of the FokI restriction site on both alleles
(defined before as ff) generates 196-bp and 69-bp
fragments, whereas the absence (FF) yields one
undigested 265-bp fragment. Heterozygous Ff
exhibits fragments of 265 bp, 196 bp, and 69 bp [19].
Statistical analysis
Data were expressed as mean and standard
deviation. Student’s t-test was used for parametric
data and Wilcoxon rank sum test (Z value) for non-
parametric data.
Differences between levels of osteocalcin, CPIP and
DPD in different Fok1 genotypes and Bsm1 genotypes
were tested using the Kruskal-Wallis test in all
genotypes. Mann-Whitney test was used to assess
the difference among different Bsm1 and Fok1
genotype subgroups and between cases with Z score
for spine and for hip less than –1 and those with
Z score more than –1 as regards the level of
osteocalcin, CPIP or DPD (data were presented as
median and IQR – inter-quartile range). Pearson
correlation coefficient, r, defines the strength and
direction of the linear relationship between Z score
and other parameters. Chi-square test, χ2, and
Fisher’s exact test were used to test the difference in
proportions of cases with Z score for spine and for
hip less than –1 and those with Zscore more than –1,
between Fok1, and Bsm1 genotypes, in total, in male
and female cases. Value of p < 0.05 was taken as
significant. The data were analysed using SPSS
(version 15). 
Results 
The results are illustrated in Tables I-VI and
Figures 1, 2.  
Age and sex distribution in the control 
group did not significantly differ from the patient
group (Table I). There were significantly higher con  -
centrations of urinary deoxypyridinoline (DPD) levels
in thalassaemic children (157.41 ±116.92 mmol/mmol
creat) than controls (53.96 ±39.37 mmol/mmol
creat) (p < 0.001). Lower levels of both serum
osteocalcin (5.68 ±8.85 ng/ml) and CPIP (193.57
±225.42 ng/ml) were found in thalassaemic patients
compared to controls (45.04 ±28.83, 398.13 ±201.85
ng/ml respectively) (p < 0.001). 
Among the thalassaemics, the spine Z score had
a mean value of –0.48 ±0.93 (median –0.54); 
the hip Z score had a mean value of –0.08 ±0.70
(median 0.17). Twenty-five percent of the studied
thalassaemics (7/28) showed a Z score < –1 at the
spine and 15.4% (4/26) had a Z score < –1 at the hip
site. Table II and Figures 1, 2 show a highly
significant negative correlation between spine
Z score and hip Z score in relation to age at
examination and a non-significant correlation
between Z score and the studied laboratory markers
of bone turnover. There was no correlation between
the BMD and serum ferritin or pre-transfusion
haemoglobin levels. Comparison between thalas  -
saemic children with fair and bad chelation shows
a non-significant difference in BMD and serum
levels of osteocalcin, CPIP, and urinary levels of DPD
in relation to chelation adequacy (p > 0.05).
No statistical significant difference in osteocalcin,
CPIP and DPD was found between cases with either
Z score for spine or hip < –1 and those with Z score
> –1 (p > 0.05) (Table III).
Significant younger mean age of studied male
patients (8.7 ±2.93 years) was found than that of
female patients (11 ±2.25 years) (p < 0.05). Lower
Z score of the lumbar spine was detected in males
(0.49 ±0.06) than that found in females (0.55 ±0.08)
(p < 0.05).  
Tables IV, V reveal no statistically significant
difference in the distribution of either Fok1 or Bsm1
genotypes between thalassaemic patients with
Z score (spine and/or hip) < –1 and those with
Z score > –1 (p > 0.05). A significantly higher
frequency of Ff alleles (66.7%) was found in
thalassaemic males with Z score of spine and/or 
hip < –1 than those with corresponding Z score 
> –1 (p = 0.04 and p = 0.03 respectively). All male
thalassaemic children (100%) with bb genotype had
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Z score (spine and/or hip) < –1 vs. none with BB or
Bb alleles (p = 0.004, p = 0.002 res  pectively). 
Table VI shows no statistically significant
difference between osteocalcin, CPIP or DPD in
different Fok genotypes (p > 0.05) in males and fe  -
ma  les. Thalassaemic children with bb genotype had
significantly higher osteocalcin levels than detected
in those with either BB or Bb alleles (p = 0.02). 
Discussion
We carried out a study on BMD, biochemical and
VDR (Bsm1, Fok1) genetic profiles in prepubertal
children with β-thalassaemia major with the hope
of gaining new insight into establishing early
predictors for these bone changes. 
The study revealed a highly significant increase
in concentration of urinary deoxypyridinoline and
lower levels of serum CPIP and osteocalcin in
studied thalassaemic children compared to controls
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Figure 1. Pearson correlation study between Z score
of the spine by DEXA and the age of thalassaemic
patients
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Figure 2. Pearson correlation study between Z score
of the hip by DEXA and the age of thalassaemic
patients in years
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Parameter Patients (n=31) Controls (n=43) Test of significance
Age [years] Mean ± SD 9.74 ±2.85 9.33 ±2.99 t value = 0.607
Range 4-14 5-15 p = 0.54
Male : female ratio 17 : 14 22 : 21
Mean pre-transfusion haemoglobin [gm/dl] Mean ± SD 7.2 ±1.9 
Range 6.9-8.2
Mean serum ferritin [ng/ml] Mean ± SD 910 ±823
Range 550-1750
Osteocalcin [ng/ml] Mean ± SD 5.68 ±8.85 45.04 ±28.83 Z value= –5.84
Range 1-48.5 0.3-105 p < 0.001
CPIP [ng/ml] Mean ± SD 193.57 ±225.42 398.13 ±201.85 Z value= –4.02
Range 1-892 49-731 p < 0.001
DPD [mmol/mmol creat] Mean ± SD 157.41 ±116.92 53.96 ±39.37 Z value = –4.62
Range 30-459 8-208 p < 0.001
Table I. Comparison between patients and controls as regards clinical and laboratory data (using Student’s t-test and
Wilcoxon rank sum test)
Parameter Spine Femur Hip
Z score Z score Z score 
Age [years] r = –0.6367 r = –0.3236 r = –0.616
p < 0.0001 p = 0.10 p < 0.0001
Mean  r = –0.15 r = –0.127 r = –0.098
pre-transfusion p =0.43 p = 0.53 p = 0.63
Hb [gm/dl]
Mean serum  r = –0.35 r = –0.369 r = –0.368
ferritin [ng/ml]  p = 0.06 p = 0.06 p = 0.06
Osteocalcin r = –0.041 r = –0.14 r = –0.05
[ng/ml]  p = 0.83 p =0.49 p =0.79
CPIP [ng/ml] r = –0.018 r = –0.04 r = –0.02
p = 0.92 p = 0.84 p = 0.91
DPD r = 0.218 r = 0.115 r = 0.312
[mmol/mmol  p = 0.27 p = 0.58 p = 0.12
creat]
Table II. Correlation between BMD in thalassaemic
patients and different clinical and laboratory
parameters (Pearson correlation coefficient)
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(p < 0.001). These results are in agreement with
Morabito  et al. [20]. These results reflect
derangement of bone metabolism with increased
bone turnover in thalassaemic children which
started early in the prepubertal period [21]. This is
supported by the finding of a significant negative
correlation between reduced BMD at studied sites
(hip and spine) and increased patient age. These
findings are in parallel with the data published by
Christoforidis et al. [22], who demon  strated a delay
in bone mass acquisition with advancing age in the
thalassaemic group compared to controls.
Reduced BMD (Z score < –1) was detected in
25% at the spine and 15.4% at the hip of studied
Z score for spine
Bone  BMD < –1 (N = 7)  BMD > –1 (N = 20) Value of p
marker
Median IQR Median IQR
Osteocalcin 3.70 1.30 7.85 1.65 1.20 4.60 0.57
CPIP 180.00 92.50 298.00 159.00 13.00 374.50 0.92
DPD 70.80 64.25 142.00 150.50 83.50 254.00 0.22
Z score for hip
Bone  BMD < –1 (N = 4) BMD > –1 (N =23) Value of p
marker
Median IQR Median IQR
Osteocalcin 4.10 1.30 8.65 1.70 1.20 4.60 0.58
CPIP 180.00 92.50 247.50 171.00 13.00 374.50 0.98
DPD 75.25 64.25 246.50 100.50 81.50 237.00 0.68
Table III. Comparison of biochemical markers between thalassaemic patients with Z score less than –1 and those with
Z score more than –1 for either spine or hip (Mann-Whitney test)
• IQR – inter-quartile range
Total patients
Fok genotypes Z score for spine (27) Value of  Z score for hip (28) Value of
< –1 (7) > –1 (20) < –1 (4) > –1 (24)
N % N % N % N %
FF 2 18.2 9 81.8 1 9.1 10 90.9
Ff 5 45.5 6 54.5 3 27.3 8 72.7
ff 5 100.0 6 100.0
Male patients
Fok genotypes Z score for spine (11) Value of Z score for hip (12) Value of
< –1 (2) > –1 (9) < –1 (2) > –1 (10)
N % N % N % N %
FF 6 100.0 6 100.0
Ff 2 66.7 1 33.3 2 66.7 1 33.3
ff 2 100.0 3 100.0
Female patients
Fok genotypes Z score for spine (16) Value of Z score for hip (16) Value of
< –1 (5) > –1 (11) < –1 (2) > –1 (14)          
N % N % N % N %
FF 2 40.0 3 60.0 1 20.0 4 80.0
Ff 3 37.5 5 62.5 1 12.5 7 87.5
ff 3 100.0 0 0 3 100.0
Table IV. Comparison of the distribution of Fok1 genotypes between thalassaemic patients with Z score for spine or hip
less than –1 and Z score more than –1 (Mann-Whitney test)
0.12
p p
0.25
0.04 0.03
0.43 0.71
p p
p p
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prepubertal thalassaemic children. This result
reflects prominent and more frequently detected
reduced BMD at the lumbar spine, which is
proposed to be an interesting site for screening for
early bone changes in those cases to call for more
intensive and preventive treatment at this age
period [23]. Significantly lower BMD of spine was
found in male than in female cases. A similar
gender difference of BMD was found by
Christoforidis et al. [22]. 
Reduced BMD was found more frequently 
in male cases with genotypes bb and Ff, but 
a non-significant correlation was found between
either Bsm1 or Fok1 allele distribution in female
cases and BMD. This result is confirmed by the
finding of significantly higher osteocalcin levels
Total patients
Bsm1  Z score for spine (28) Value of Z score for hip (29) Value of
genotypes
< –1 (7) > –1  (21) < –1 (4) > –1  (25)
N % N % N % N %
BB 3 25.0 9 75.0 1 8.3 11 91.7
Bb 2 20.0 8 80.0 1 9.1 10 90.9
bb 2 33.3 4 66.7 2 33.3 4 66.7
Male patients
Bsm1 Z score for spine (11) Value of Z score for hip (12)             Value of
genotypes
< –1 (2)               > –1  (14) < –1 (2) >-1 (14)
N % N % N % N %
BB 4 100.0 4 100.0
Bb 5 100.0 6 100.0
bb 2 100.0 2 100.0
Female patients
Bsm1 Z score for spine (17) Value of Z score for hip (17)             Value of
genotypes
<– 1  (5)                 > –1 (12) < –1 (2) > –1  (15)
N % N % N % N %
BB 3 37.5 5 62.5 1 12.5 7 87.5
Bb 2 40.0 3 60.0 1 20.0 4 80.0
bb 0 0 4 100.0 0 0 4 100.0
Table V. Comparison of the distribution of Bsm1 genotypes between thalassaemic patients with Z score for spine or hip
less than –1 and Z score more than –1 (Mann-Whitney test)
Fok1 genotype
FF Fff f Value of
Median IQR Median IQR Median IQR
p
Osteocalcin 1.40 1.20 2.75 2.20 1.45 7.85 9.10 1.20 9.50 0.11
CPIP 187.00 89.50 424.00 180.00 14.50 380.00 59.30 12.00 147.00 0.55
DPD 97.30 68.00 290.80 82.00 68.15 142.00 177.25 51.00 254.00 0.64
Bsm1 genotype
BB Bb bb Value of
Median IQR Median IQR Median IQR
p
Osteocalcin 1.50 1.20 2.95 1.90 1.25 7.25 10.40 10.40 11.70 0.02
CPIP 175.50 14.50 454.00 180.00 11.00 292.50 100.60 100.60 281.00 0.66
DPD 85.00 75.90 204.50 218.00 68.00 308.80 65.50 65.50 85.00 0.46
Table VI. Comparison between the studied biochemical markers in different studied Fok1 and Bsm1 genotypes 
of thalassaemic children (Kruskal-Wallis test)
0.84 0.30
0.004 0.002
0.33 0.65
p p
p p
p p
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in thalasseamic males with bb genotype than
levels detected in those with either BB or Bb
alleles, which reflects increased bone turnover in
those cases. These findings support the
involvement of Bsm1 and Fok1 genotypes as
a determinant of BMD in male prepubertal thalas  -
saemic children [18]. The significant gender
difference within a particular genetic pattern may
be attributed to the significant younger age of
studied males than that of females based on the
concept that BMD is genetically determined in
early age before puberty.
Moreover, no significant difference of studied
biochemical indices was detected between
thalassaemic children with reduced BMD and those
with normal BMD. These results are contradictory
to Angelopoulos et al. [24]. These findings suggest
that BMD assessment by DEXA may be a sensitive
predictor for early bone changes in this particular
age [25].
No significant difference of either BMD or studied
biochemical indices was found between thalas  -
saemic children with fair and bad chelation. 
In addition to the insignificant correlation of reduced
BMD with the mean pre-transfusion haemoglobin,
these results suggest a weak contribution of
anaemia and chelating therapy in early bone
derangement in prepubertal patients [21].
In conclusion, the present study indicates a delay
in bone mass acquisition with advancing age in
prepubertal thalassaemic children. Studied Egyptian
male thalasseamic children with genotypes bb and
Ff had a higher rate of bone turnover, supporting
the involvement of Bsm1 and Fok1 polymorphisms
as determinants of BMD before puberty with
a gender difference. Early diagnosis should be done
during childhood to improve quality of life in
adulthood. We recommend early routine BMD
screening before puberty, which is proposed to be
a sensitive predictor for early bone changes, in
particularly at the lumbar spine. Further prospective
studies on a wider scale are required to fully clarify
the precise environmental and genetic mechanisms
underlying bone metabolism derangement in
thalassaemic children. 
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